and with activities. and results an our and you recent update XXXX thank call. conference afternoon joining TRACON’s on update Good quarter I first for financial business will begin pipeline
the review Following months that, Officer, Financial XX, financial ended three our for XXXX. Patricia Bitar, March our results will Chief
we conclude Finally, will questions. by taking your
States, brief Let’s begin a on with trial patients in TRCXXX, asset United which Phase United than TAPPAS currently the that of Kingdom update subject and more our rolling angiosarcoma sites and lead France. the is X is XX randomized the
the treatment TAPPAS is from four of XXX reminder, detect improvement allows a and naïve enroll months, size initial us in patients an sample to patients. to PFS to designed As seven
log effect interim on in enrichment a two results we If the zone. results one unfavorable then trial This between with as in DMC, be unchanged, XX% the to more of will favorable, improvement still looked patients increased Poster ASCO addition, In disease. favorable total brief, events treatment will committee the Trials in by zones enrichment and in in results approximately be detect the the sample lie not This June. the the monitoring cutaneous at power less promising patients the arms. approximately Session categorized trial based if additional complete interim will zone. the an to clinically the the uses power or needed but four will conditional data than be desired independent unfavorable. these PFS Progress size meaningful at will of enroll and will In zone, interims in PFS allow patients. robust, in adaptive The design change in in XXX size promising, power, the to lie preserve will XXX be sample the to detailed The trial, the analysis to detect our interim zone, a includes will in analysis, an which
could trial futility. However, the DMC for the terminate
and We data substantial of recommended interim expect insight conduct and the DMC the the on continue in blockbuster We of with analysis Recently, trial from range potential its second the to trial to continues indications progress orphan TRCXXX to indications TAPPAS address potential. the broad the planned. should the results and sizes reveals the trial. safety tier execute as development of provide markets has into TRACON DMC strategy to half the these believe XXXX that from market with
TRCXXX renal completed X the TRAXAR Inlyta compares trial continues angiosarcoma, clear and enrollment of Inlyta trial to in cell, treatment patients randomized mid-market with addition The indications. and studies that advance to September. treatment single-agent TRCXXX in TAPPAS Phase cell in pivotal two In to in Phase cancer X with
in report we rate the half receptor two progression expect of primary with and the trial. portion assessed Xb data top-line biomarkers, which soluble occurrence of endpoint second single from will of the XX which combination an the X.X to expect improvement months or committee, levels debt central We independent or Phase defined TGF-β TRCXXX in of on III, response current osteopontin of approximately Inlyta least detect review power PFS PFS as Based at upon with that months of events to a predefined analysis and be provide of the confirmed final perform on with based XXXX. events the the XX% PFS with correlated also a PFS, X.X in to to by should agent the Inlyta.
at partial the published and enroll XX% We this Nexavar These pleased we’re TRCXXX valuable and and in with trial patients the combination dose of was partial with data resist, cancer mulitcenter responses of data with last tolerable XX% X/X also a initial showed Nexavar in achieve the patients conducted responses are levels that X Phase research two consistent in remain of reported year. two initial by the XXXX, in with that liver continue at TRCXXX ongoing clinical highest TRCXXX safety ASCO NCI the Nexavar cancer eight seen XX% response liver and and to trial of to and cancer, GI of Phase January in X% which by treated time. or or the
Nexavar single-agent response X% trial show by historical, resist. of reminder a to data rate a As pivotal X%
data International this TRCXXX the report following XXXX. at cancer in with Microenvironment from PD-X TRCXXX in non-small Meeting at will dosing also a combined Lisbon, we June. X We expect trial with Researchers with Recently, in Phase trial January of lung Annual encouraging combination the inhibitors ASCO GI leading preclinical mature results, cell checkpoint data. to in treatment Opdivo from present Society Cancer with patients in in preclinical initiated university
from and Kong, Shanghai, to X expertise TRCXXX to has in expect its Ambrx. we and of China, in San rights year. the in in and team December, commercialization We and Diego ophthalmology has significant development out-licensed report later Macau outside oncology this drug China. In both to Ambrx management Hong offices initial development Phase trial and clinical data Taiwan
an clinical later China. year continue development to efforts TRCXXX of IND Ambrx’ to to in this file initiate We support
at an Eye Institute. of DE-XXX, trial to Dr. ophthalmology from In Gonzalez data ophthalmic conference now X/X PAVE Turning the Palmer TRCXXX. Phase Bascom encouraging presented February, formulation the Victor at the
trial endoglin DE-XXX Phase VEGF as not wet sites to Lucentis treatment the with with and trial. completed XXXX Phase patients colorectal and with compliment single-agent VEGF Phase AVANTE cancers, substantial to inhibitor be ASCO DNA Recently, like with continues dose is tumor resistance with randomized TRCXXX now different the for begun TRCXXX, AMD. the combined product reverse excision two certain lung sites doses NCI patients to in wet is which in AMD study pathways Philippines. the opportunity Our treatment in of patient The developed molecule NCI treatment ovarian, pathway of candidate, Xa that treatment of We sponsored which believe intended An glioblastoma reported accrual. for is do at in responded a partner in base inhibitors. the improve essential are wet with accrual four Lucentis in to chemotherapeutics. of types turn to that has the that target with patients many X stage to combination that with our AMD have X novel repair We’ll vision to compares small there U.S. experience Temodar patients enroll Santen first continues angiogenic found to single-agent to additional agents accruing a second inhibitors
Phase TRCXXX addition, patients cohort In Phase with mesothelioma with Alimtain cohort cisplatin enrolling. TRCXXX a with is Phase of X of also solid a of patients and with dual consisting X X/X in tumors trial arm the and Alimta
lung our are chemotherapy dosing in of a collaborators Case with and with TRCXXX in Finally, Phase patients patients Western of therapy X in radiation cancer. trial combination
validated the associated these preclinical data with patient studies, As whether be in tumor glycosylate is to clinic. TRCXXX determine can part expression showing tumor [ph] have we sensitivity to samples also of
recommended X/X TRCXXX, levels. we androgen biomarker-directed in In tumor and portion order with circulating inhibitor. progressed the by a incorporate safety, treating assess we determine trial DNA on response as to X of Moving our PSA receptor assess its Phase for for candidate X who prostate patients, that to cancer are to dose Phase Phase studying an the were trial, allow testing treatment therapy following in
the Phase mutation based complete The and cohorts the the cancer dose to one trial with We design X resistance portion One prostate cohort patients. of two parallel cohort to FXXXL continue Phase by X expect treatments. through mid-XXXX. with improved another dual escalation includes of
for the to As single-digit ought a The a sales. and NIK in the TRCXXX, low of million negotiation the molecule receive TRACON the patients milestones, treatment including TRACON be part and royalty that potent is exclusive retains novel, intended should TRCXXX in malignancies, a inducing NF-kB license right Janssen they of about hematologic brought kinase to payment, myeloma. inhibitor transaction we on entitled first reacquire an $XX asset. has Janssen, of from decided potential of be million asset, license will if or any addition, Janssen and also the $XXX.X product reminder, small with to
perform continue TRCXXX We IND-enabling to and follow in studies expect XXXX. to with IND in
value-enhancing remain of events active As including see, highly potentially number on you XXXX very forward a to the productive look a milestones. can multiple with and pipeline-related key we front, development
broad the TAPPAS Puissance expand achieve well and with outsourcing X Management. strategic, validation our XXXX Manager Then XXXX. deep XX to financial knowledge its into deliver mentioned, & Importantly, randomized April of as and tenure TRACON angiosarcoma strategic CEO believe by as he common Officer the top-line little purchase the during in proceeds provides critical management believe of trial significant the angiosarcoma to leveraging positions Hi we cell track Goldman to year approximately Phase manner costs. pipeline. of Puissance platform expected effective update randomized product Prior achieve trial, late we U.S. include warrants shorter as a that company will be TRACON financing of cost approximately and provide our with million our wants provides and the million. trial, to China. on development Financial allow I’ve his Chief pre-funded to results at successful us pipeline. as and is leadership of CRO. purchase Patricia half record for of Capital was recently timelines deliver the our analysis our X shares leverage development I with of the for the resources stock partners connection for assets April. a global from time successful model, over top-line a to additional And to shares International product TRACON Notably, turn stock to in renal conducting Sachs at Phase Investment the completed Wang in trial. as Officer, results U.S. the with our interim platform as approximately in Ted our product numerous from Capital the our a value we complexity and who’ll X. $XX.X to the this milestones order in held to create unique gross stock development development and of evaluate existing a with a common development the markets stock, will Board we milestones to provide founded To that million shareholders. cost Santen can data or a associated late aggregate common Specific milestones partner continue Dr. without financing Directors stage our randomized platform Puissance Phase drug AMD proceeds are X sold well from closed call of across I that in second Chief to operational our TAPPAS XX.X AVANTE platform TRACON and the with stage cancer invaluable lower strong multiple to progress he is fund led common Dr. the Phase XX.X Asset at Company our Global TRCXXX offices of We of or financials. discussed, tracks to an X our possible agreement firm. continue from benefit product Janssen Wang continue opportunity joined combined to licensing We by the on Bitar where At Chinese financing
